drugset
drugset / Trial / NCT04150757

Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

NCT04150757 ↗

Phase 3 Terminated 5 enrolled Abigail Nixon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This will be a descriptive cohort study of intranasal ketamine as the initial analgesic for children with sickle cell disease who present to the pediatric emergency department with vaso-occlusive crisis and are awaiting intravenous line placement.

Timeline

Start
2019-12-19
Primary completion
2020-10-01
Completion
2022-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 1 mg/kg Intranasal

Indications

sickle cell disease